Asher Biotherapeutics
Latest round
- Series C
Last raised
- Apr 2024
Total raised
- $218M
Investors
- 13
About Asher Biotherapeutics
Based in California, US, and founded in 2019, Asher Biotherapeutics, Inc. operates as a biotechnology company that develops precision immune-cell targeting therapeutics for patients with cancer, autoimmune disease, and infectious disease. The company was co-founded by Dr. Ivana Djuretic and Dr. Andy Yeung. Asher Biotherapeutics provides cis-targeted immunotherapies that offer a new level of selectivity that delivers superior clinical outcomes and an improved safety profile. The company's platform is CIS-Targeting and TRANS-Targeting that focuses on two receptors on the same cell and two different cells. Asher Bio’s treatments target an immunomodulatory receptor and a marker found only in the immune cells it wants to activate. The company's lead program, AB248, is designed to activate CD8+ killer T cells while leaving other immune cells such as regulatory T cells, natural killer cells and endothelial cells alone.S. Food and Drug Administration in the third quarter of 2022.
Who invested in Asher Biotherapeutics
13 investors across 3 rounds
See all investors in Asher Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Asher Biotherapeutics
Who invested in Asher Biotherapeutics?
Asher Biotherapeutics has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Asher Biotherapeutics raised?
Asher Biotherapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Asher Biotherapeutics last raise money?
Asher Biotherapeutics's most recent round on record is a Series C, in Apr 2024.
What does Asher Biotherapeutics do?
Based in California, US, and founded in 2019, Asher Biotherapeutics, Inc.
Where is Asher Biotherapeutics headquartered?
Asher Biotherapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Asher Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Asher Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Asher Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.